Intravenous thrombolysis and mechanical recanalization for acute ischemic stroke in deep brain stimulation patients: a case series.

"Declarations Conflicts of interestDr. Meyne reports no conflicts of interest. Dr. Domschikowski reports no conflicts of interest. Dr. Hensler reports no conflicts of interest. Dr. Helmers reports no conflicts of interest. Dr. Berg received consultancies/advisory board fees for Biogen, BIAL, UCB Pharma GmbH, Zambon, honoraria for talks/lectures from AbbVie, Bayser, Biogen, BIAL, UCB Pharma GmbH, Zambon, and Desitin and grants/research funding from Deutsche Forschungsgemeinschaft (DFG), German Parkinson’s Disease Association (dPV), BMBF, Parkinson Fonds Deutschland gGmbH, UCB Pharma GmbH, EU, Novartis Pharma GmbH, Lundbeck, and the Damp Foundation. Dr. Deuschl received fees for lecturing from Boston Scientific and consulting fees from Boston Scientific, Cavion, Functional modulation. He receives funding for his research to his institution from the German Research Council, SFB 1261, B5, and Medtronic. Dr. Paschen reports speaker honoraria from Insightec, AbbVie, Medtronic GmbH and Boston Scientific outside the submitted work and travel grants from Desitin and Abbvie and grant/research funding from Parkinson Fonds Deuschland gGmbH and UCB Pharma GmbH. Research ethicsThe study was approved by the local ethics committee (D497/22). Based on the ethics committee decision, informed consent was not obtained. Classification of evidenceThis study provides class IV evidence that IVT and MT may be applied in patients with DBS and ischemic stroke based on an individual risk-benefit analysis, taking into account the time between previous DBS surgery and IVT and/or MT.” Conflicts of interest Dr. Meyne reports no conflicts of interest. Dr. Domschikowski reports no conflicts of interest. Dr. Hensler reports no conflicts of interest. Dr. Helmers reports no conflicts of interest. Dr. Berg received consultancies/advisory board fees for Biogen, BIAL, UCB Pharma GmbH, Zambon, honoraria for talks/lectures from AbbVie, Bayser, Biogen, BIAL, UCB Pharma GmbH, Zambon, and Desitin and grants/research funding from Deutsche Forschungsgemeinschaft (DFG), German Parkinson’s Disease Association (dPV), BMBF, Parkinson Fonds Deutschland gGmbH, UCB Pharma GmbH, EU, Novartis Pharma GmbH, Lundbeck, and the Damp Foundation. Dr. Deuschl received fees for lecturing from Boston Scientific and consulting fees from Boston Scientific, Cavion, Functional modulation. He receives funding for his research to his institution from the German Research Council, SFB 1261, B5, and Medtronic. Dr. Paschen reports speaker honoraria from Insightec, AbbVie, Medtronic GmbH and Boston Scientific outside the submitted work and travel grants from Desitin and Abbvie and grant/research funding from Parkinson Fonds Deuschland gGmbH and UCB Pharma GmbH."

"Funding Open Access funding enabled and organized by Projekt DEAL. This research received no specific grant from any funding agency in the public, commercial, or not-for profit-sectors."